Osteoimmunology and its implications for transplantation

American Journal of Transplantation

Volumn 13, Issue 9, 2013, Pages 2245-2254

  Pacifici, R ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Bone; PTH

Indexed keywords

ESTROGEN; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 7; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR; WNT10B PROTEIN;

B LYMPHOCYTE; BIOSYNTHESIS; BONE METASTASIS; CALCIUM METABOLISM; CATABOLISM; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CORTICAL BONE; CYTOKINE RELEASE; HEMATOPOIETIC STEM CELL; IMMUNE RESPONSE; IMMUNOLOGY; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOIMMUNOLOGY; OSTEOLYSIS; PERIODONTITIS; POSTMENOPAUSE OSTEOPOROSIS; PRE B LYMPHOCYTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STEM CELL EXPANSION; STROMA CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH17 CELL; TRABECULAR BONE; TRANSPLANTATION;

BONE; PTH;

ANIMALS; B-LYMPHOCYTES; BONE AND BONES; BONE MARROW TRANSPLANTATION; BONE RESORPTION; BONE TRANSPLANTATION; CD40 LIGAND; ESTROGENS; HEMATOPOIESIS; HUMANS; LYMPHOCYTE ACTIVATION; MICE; OSTEOGENESIS; OSTEOPOROSIS; OSTEOPROTEGERIN; OVARIECTOMY; PARATHYROID HORMONE; T-LYMPHOCYTES;

EID: 84883462844     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12380     Document Type: Review

References (86)

1. Stein E, Ebeling P, Shane E., Post-transplantation osteoporosis. Endocrinol Metabol Clin North America 2007; 36: 937-963; viii.
2. Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402: 304-309.
3. Teng YT, Nguyen H, Gao X, et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest 2000; 106: 59-67.
4. Zhang K, Kim S, Cremasco V, et al. CD8+ T cells regulate bone tumor burden independent of osteoclast resorption. Cancer Res 2011; 71: 4799-4808.
5. Pacifici R., Role of T cells in ovariectomy induced bone loss-revisited. J Bone Miner Res 2012; 27: 231-239.
6. Li Y, Toraldo G, Li A, et al. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 2007; 109: 3839-3848.
7. Li JY, Tawfeek H, Bedi B, et al. Ovariectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligand. Proc Natl Acad Sci USA 2011; 108: 768-773.
8. Li JY, Adams J, Calvi LM, et al. PTH expands short-term murine hemopoietic stem cells through T cells. Blood 2012; 120: 4352-4362.
9. Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI., Human nutrition, the gut microbiome and the immune system. Nature 2011; 474: 327-336.
10. Sjogren K, Engdahl C, Henning P, et al. The gut microbiota regulates bone mass in mice. J Bone Miner Res 2012; 27: 1357-1367.
11. Sato K, Suematsu A, Okamoto K, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006; 203: 2673-2682.
12. Polanczyk MJ, Carson BD, Subramanian S, et al. Cutting edge: Estrogen drives expansion of the CD4+ CD25+ regulatory T cell compartment. J Immunol 2004; 173: 2227-2230.
13. Zaiss MM, Axmann R, Zwerina J, et al. Treg cells suppress osteoclast formation: A new link between the immune system and bone. Arthritis Rheum 2007; 56: 4104-4112.
14. Zaiss MM, Frey B, Hess A, et al. Regulatory T cells protect from local and systemic bone destruction in arthritis. J Immunol 2010; 184: 7238-7246.
15. Zaiss MM, Sarter K, Hess A, et al. Increased bone density and resistance to ovariectomy-induced bone loss in FoxP3-transgenic mice based on impaired osteoclast differentiation. Arthritis Rheum 2010; 62: 2328-2338.
16. Fujisaki J, Wu J, Carlson AL, et al. In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche. Nature 2011; 474: 216-219.
17. Kiesel J, Miller C, Abu-Amer Y, Aurora R., Systems level analysis of osteoclastogenesis reveals intrinsic and extrinsic regulatory interactions. Dev Dyn 2007; 236: 2181-2197.
18. Li H, Hong S, Qian J, Zheng Y, Yang J, Yi Q., Cross talk between the bone and immune systems: Osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells. Blood 2010; 116: 210-217.
19. Buchwald ZS, Kiesel JR, DiPaolo R, Pagadala MS, Aurora R., Osteoclast activated FoxP3+ CD8+ T-cells suppress bone resorption in vitro. PLoS ONE 2012; 7: e38199.
20. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95: 3597-3602.
21. Yun TJ, Chaudhary PM, Shu GL, et al. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol 1998; 161: 6113-6121.
22. Li Y, Li A, Yang X, Weitzmann MN., Ovariectomy-induced bone loss occurs independently of B cells. J Cell Biochem 2007; 100: 1370-1375.
23. Onal M, Xiong J, Chen X, et al. Receptor activator of nuclear factor kappaB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem 2012; 287: 29851-29860.
24. Weitzmann MN, Pacifici R., Estrogen deficiency and bone loss: An inflammatory tale. J Clin Invest 2006; 116: 1186-1194.
25. Nakamura T, Imai Y, Matsumoto T, et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 2007; 130: 811-823.
26. Krum SA, Miranda-Carboni GA, Hauschka PV, et al. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J 2008; 27: 535-545.
27. Manolagas SC., From estrogen-centric to aging and oxidative stress: A revised perspective of the pathogenesis of osteoporosis. Endocr Rev 2010; 31: 266-300.
28. Jilka RL, Takahashi K, Munshi M, Williams DC, Roberson PK, Manolagas SC., Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. J Clin invest 1998; 101: 1942-1950.
29. Di Gregorio GB, Yamamoto M, Ali AA, et al. Attenuation of the self-renewal of transit-amplifying osteoblast progenitors in the murine bone marrow by 17beta-estradiol. J Clin Invest 2001; 107: 803-812.
30. Kousteni S, Bellido T, Plotkin LI, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: Dissociation from transcriptional activity. Cell 2001; 104: 719-730.
31. Kousteni S, Han L, Chen JR, et al. Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J Clin Invest 2003; 111: 1651-1664.
32. Cenci S, Weitzmann MN, Roggia C, et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest 2000; 106: 1229-1237.
33. Roggia C, Gao Y, Cenci S, et al. Up-regulation of TNF-producing T cells in the bone marrow: A key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci USA 2001; 98: 13960-13965.
34. Gao Y, Qian W-P, Dark K, et al. Estrogen prevents bone loss through transforming growth factor {beta} signaling in T cells. Proc Natl Acad Sci USA 2004; 16618-16623.
35. Gao Y, Grassi F, Ryan MR, et al. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest 2007; 117: 122-132.
36. Yamaza T, Miura Y, Bi Y, et al. Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. PLoS ONE 2008; 3: e2615.
37. Grassi F, Tell G, Robbie-Ryan M, et al. Oxidative stress causes bone loss in estrogen-deficient mice through enhanced bone marrow dendritic cell activation. Proc Natl Acad Sci USA 2007; 104: 15087-15092.
38. Lee SK, Kadono Y, Okada F, et al. T lymphocyte-deficient mice lose trabecular bone mass with ovariectomy. J Bone Miner Res 2006; 21: 1704-1712.
39. Gao Y, Qian WP, Dark K, et al. Estrogen prevents bone loss through transforming growth factor beta signaling in T cells. Proc Natl Acad Sci USA 2004; 101: 16618-16623.
40. Robbie-Ryan M, Pacifici R, Weitzmann MN., IL-7 drives T cell-mediated bone loss following ovariectomy. Ann N Y Acad Sci 2006; 1068: 348-351.
41. DeSelm C, Takahata Y, Chappel J, et al. IL-17 mediates estrogen-deficient osteoporosis. Cell Biochem 2012; 113: 2895-2902.
42. Lelu K, Laffont S, Delpy L, et al. Estrogen receptor alpha signaling in T lymphocytes is required for estradiol-mediated inhibition of Th1 and Th17 cell differentiation and protection against experimental autoimmune encephalomyelitis. J Immunol 2011; 187: 2386-2393.
43. Goswami J, Hernandez-Santos N, Zuniga LA, Gaffen SL., A bone-protective role for IL-17 receptor signaling in ovariectomy-induced bone loss. Eur J Immunol 2009; 39: 2831-2839.
44. DeSelm CJ, Takahata Y, Warren J, et al. IL-17 mediates estrogen-deficient osteoporosis in an Act1-dependent manner. J Cell Biochem 2012; 113: 2895-2902.
45. Tai P, Wang J, Jin H, et al. Induction of regulatory T cells by physiological level estrogen. J Cell Physiol 2008; 214: 456-464.
46. Tyagi AM, Srivastava K, Sharan K, Yadav D, Maurya R, Singh D., Daidzein prevents the increase in CD4CD28null T cells and B lymphopoesis in ovariectomized mice: A key mechanism for anti-osteoclastogenic effect. PLoS ONE 2011; 6: e21216.
47. D'Amelio P, Grimaldi A, Di Bella S, et al. Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: A key mechanism in osteoporosis. Bone 2008; 43: 92-100.
48. Cenci S, Toraldo G, Weitzmann MN, et al. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc Natl Acad Sci USA 2003; 100: 10405-10410.
49. Grassi F, Pacifici R., Ovariectomy increases the formation of T cell niches at the resorption surfaces. J Bone Min Res 2005; 20 (Suppl 1): Abs.
50. Lean JM, Davies JT, Fuller K, et al. A crucial role for thiol antioxidants in estrogen-deficiency bone loss. J Clin Invest 2003; 112: 915-923.
51. Muthusami S, Ramachandran I, Muthusamy B, et al. Ovariectomy induces oxidative stress and impairs bone antioxidant system in adult rats. Clin Chim Acta 2005; 360: 81-86.
52. Tyagi AM, Srivastava K, Kureel J, et al. Premature T cell senescence in ovx mice is inhibited by repletion of estrogen and medicarpin: A possible mechanism for alleviating bone loss. Osteoporos Int 2011; 23: 1151-1161.
53. Basu S, Michaelsson K, Olofsson H, Johansson S, Melhus H., Association between oxidative stress and bone mineral density. Biochem Biophys Res Commun 2001; 288: 275-279.
54. Maggio D, Barabani M, Pierandrei M, et al. Marked decrease in plasma antioxidants in aged osteoporotic women: Results of a cross-sectional study. J Clin Endocrinol Metab 2003; 88: 1523-1527.
55. Finkel T., Oxidant signals and oxidative stress. Curr Opin Cell Biol 2003; 15: 247-254.
56. Ozaki M, Suzuki S, Irani K., Redox factor-1/APE suppresses oxidative stress by inhibiting the rac1 GTPase. FASEB J 2002; 16: 889-890.
57. Almeida M, Han L, Martin-Millan M, et al. Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem 2007; 282: 27285-27297.
58. Almeida M, Martin-Millan M, Ambrogini E, et al. Estrogens attenuate oxidative stress and the differentiation and apoptosis of osteoblasts by DNA-binding-independent actions of the ERalpha. J Bone Miner Res 2010; 25: 769-781.
59. Martin-Millan M, Almeida M, Ambrogini E, et al. The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol Endocrinol 2010; 24: 323-334.
60. Mizuashi M, Ohtani T, Nakagawa S, Aiba S., Redox imbalance induced by contact sensitizers triggers the maturation of dendritic cells. J Invest Dermatol 2005; 124: 579-586.
61. Rutault K, Alderman C, Chain BM, Katz DR., Reactive oxygen species activate human peripheral blood dendritic cells. Free Radic Biol Med 1999; 26: 232-238.
62. Maemura K, Zheng Q, Wada T, et al. Reactive oxygen species are essential mediators in antigen presentation by Kupffer cells. Immunol Cell Biol 2005; 83: 336-343.
63. Vosters O, Neve J, De Wit D, Willems F, Goldman M, Verhasselt V., Dendritic cells exposed to nacystelyn are refractory to maturation and promote the emergence of alloreactive regulatory t cells. Transplantation 2003; 75: 383-389.
64. Verhasselt V, Vanden Berghe W, Vanderheyde N, Willems F, Haegeman G, Goldman M., N-acetyl-L-cysteine inhibits primary human T cell responses at the dendritic cell level: Association with NF-kappaB inhibition. J Immunol 1999; 162: 2569-2574.
65. Jagger CJ, Lean JM, Davies JT, Chambers TJ., Tumor necrosis factor-alpha mediates osteopenia caused by depletion of antioxidants. Endocrinology 2005; 146: 113-118.
66. Grewal IS, Flavell RA., CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998; 16: 111-135.
67. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ., CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 2004; 22: 307-328.
68. Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002; 8: 247-252.
69. Leveille C, Bouillon M, Guo W, et al. CD40 ligand binds to alpha5beta1 integrin and triggers cell signaling. J Biol Chem 2007; 282: 5143-5151.
70. Ahuja SS, Zhao S, Bellido T, Plotkin LI, Jimenez F, Bonewald LF., CD40 ligand blocks apoptosis induced by tumor necrosis factor alpha, glucocorticoids, and etoposide in osteoblasts and the osteocyte-like cell line murine long bone osteocyte-Y4. Endocrinology 2003; 144: 1761-1769.
71. Gao Y, Wu X, Terauchi M, et al. T cells potentiate PTH-induced cortical bone loss through CD40L signaling. Cell Metab 2008; 8: 132-145.
72. Lopez-Granados E, Temmerman ST, Wu L, et al. Osteopenia in X-linked hyper-IgM syndrome reveals a regulatory role for CD40 ligand in osteoclastogenesis. Proc Natl Acad Sci USA 2007; 104: 5056-5061.
73. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-1441.
74. Canalis E, Giustina A, Bilezikian JP., Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007; 357: 905-916.
75. Tawfeek H, Bedi B, Li JY, et al. Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss. PLoS ONE 2010; 5: e12290.
76. Terauchi M, Li JY, Bedi B, et al. T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. Cell Metab 2009; 10: 229-240.
77. Bedi B, Li JY, Tawfeek H, et al. Silencing of parathyroid hormone (PTH) receptor 1 in T cells blunts the bone anabolic activity of PTH. Proc Natl Acad Sci USA 2012; 109: E725-E733.
78. Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005; 146: 4577-4583.
79. Keller H, Kneissel M., SOST is a target gene for PTH in bone. Bone 2005; 37: 148-158.
80. O'Brien CA, Plotkin LI, Galli C, et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE 2008; 3: e2942.
81. Mendez-Ferrer S, Michurina TV, Ferraro F, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010; 466: 829-834.
82. Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003; 425: 841-846.
83. Straub RH, Cutolo M, Buttgereit F, Pongratz G., Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J Intern Med 2010; 267: 543-560.
84. Straub RH., Concepts of evolutionary medicine and energy regulation contribute to the etiology of systemic chronic inflammatory diseases. Brain Behav Immun 2011; 25: 1-5.
85. Feske S., Calcium signalling in lymphocyte activation and disease. Nat Rev 2007; 7: 690-702.
86. Straub RH., Evolutionary medicine and chronic inflammatory state-known and new concepts in pathophysiology. J Mol Med (Berl) 2012; 90: 523-534.